ESMO Day 4 Wrap-Up: 10 Highlights
ADCs delivered several of Day 4’s strongest late-stage results, while targeted combinations, T-cell therapies and immunotherapy added to the discussion. Survival gains stood out, but small cohorts, immature data, and tolerability remained important caveats.
This wrap-up covers presentations delivered on October 26 only. Stock moves use the October 26 U.S. regular-session close versus October 23, with earlier figures updated where needed. They reflect the full trading day, not necessarily reactions to individual presentations.
1. Merck: two Phase 3 advances in endometrial cancer | $MRK
In TroFuse-005, TROP2 ADC sac-TMT improved median overall survival to 19.0 vs. 12.1 months after platinum chemotherapy and immunotherapy. In KEYNOTE-C93, PD-1 inhibitor Keytruda alone delivered 38.2 vs. 8.4 months median progression-free survival (PFS) in first-line dMMR disease. However, the latter trial used chemotherapy alone as its comparator, and an overall-survival benefit remains unproven. Shares fell 3.21%.
2. HUTCHMED/AstraZeneca: targeting EGFR and MET upfront | $HCM $AZN
The Phase 3 SANOVO trial evaluated MET inhibitor savolitinib plus EGFR inhibitor osimertinib in untreated EGFR-mutated, MET-overexpressing NSCLC. Median PFS reached 24.9 vs. 13.8 months with osimertinib alone, reducing progression or death risk by 44%. The China-based trial supports further development of this biomarker-selected combination. HUTCHMED fell 0.63%; AstraZeneca gained 0.33%.
3. Bristol Myers Squibb/SystImmune: bispecific ADC delivers in lung cancer | $BMY
In Phase 3 PANKU-Lung01, EGFR×HER3 bispecific ADC izalontamab brengitecan (iza-bren) improved median PFS to 11.1 vs. 5.7 months with chemotherapy in previously treated EGFR-mutated NSCLC. Confirmed response rates were 60.2% vs. 34.5%. Overall-survival data remain immature, making longer follow-up important. Bristol Myers Squibb gained 0.21%.
4. GSK/Hansoh: osteosarcoma benefit with substantial toxicity | $GSK
B7-H3 ADC risvutatug rezetecan improved median PFS to 5.5 vs. 1.4 months with chemotherapy in the China-based Phase 3 ARTEMIS-011 trial in heavily pretreated osteosarcoma. That represented a 67% reduction in progression or death risk. Grade ≥3 treatment-related adverse events occurred in 93% vs. 83%, keeping tolerability central to the discussion. GSK gained 0.69%.
5. Incyte: early KRAS G12D combinations in pancreatic cancer | $INCY
Phase 1 data for oral KRAS G12D inhibitor INCB161734 plus chemotherapy showed six-month PFS rates of 90% with modified FOLFIRINOX and 80% with gemcitabine/nab-paclitaxel in metastatic pancreatic cancer. These small, uncontrolled cohorts require randomized confirmation; the Phase 3 DAWN-303 trial is underway. Shares fell 2.07%.
6. Eikon: durable responses, sharp share decline | $EIKN
In Phase 2 TeLuRide-005, TLR7/8 agonist EIK1001 plus pembrolizumab and chemotherapy produced a 72.4% response rate among 29 evaluable patients with squamous NSCLC, with median response duration of 12.9 months. Grade ≥3 treatment-related events occurred in 48.6% of the pooled 72-patient safety population. The uncontrolled study cannot establish EIK1001’s added benefit. Shares fell 23.69%.
7. Iovance: TIL therapy shows activity in sarcoma | $IOVA
A pilot study of lifileucel tumor-infiltrating lymphocyte therapy reported confirmed responses in 4 of 8 evaluable patients with refractory undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. All four responses remained ongoing, ranging from 6+ to 46+ weeks. The findings support further investigation, but the sample is too small for firm conclusions. Shares fell 2.20%.
8. Amgen: sustained second-line survival benefit | $AMGN
Extended Phase 3 DeLLphi-304 follow-up reinforced the benefit of DLL3×CD3 T-cell engager tarlatamab in previously treated small-cell lung cancer. After approximately 23 months of follow-up, median overall survival was 13.6 vs. 8.4 months with chemotherapy, a 38% reduction in death risk. This was a durability update to the established trial results. Shares gained 1.22%.
9. MacroGenics: activity with a dose-optimization question | $MGNX
In Phase 2 LINNET, PD-1×CTLA-4 bispecific lorigerlimab achieved a 25% confirmed response rate among 16 evaluable patients with clear-cell gynecologic cancer. All responses were ongoing. Across the broader 41-patient safety population, 49% experienced grade ≥3 treatment-related events, including one treatment-related death in the ovarian-cancer cohort. A lower dose is being evaluated. Shares fell 2.67%.
10. Immunome: symptom and physical-function improvements | $IMNM
New exploratory analyses from Phase 3 RINGSIDE showed patient-reported benefits with oral gamma-secretase inhibitor varegacestat in progressing desmoid tumors. At week 48, symptom scores changed by −1.50 vs. +0.59 with placebo, while physical-function scores improved +3.90 vs. −3.04. These findings build on previously reported efficacy results. Shares fell 0.56%.

👉🏻 Follow the next milestones in the BPIQ Catalyst Calendar. Unlock our new features: BPIQ’s Prob/Mag analysis puts scenario probabilities and estimated stock moves side by side, helping investors compare potential upside, downside, and mixed outcomes. Explore the analysis for clinical readouts and upcoming FDA decisions.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 10/26/26 MD

%20-%20button.png)
Comments